Clinical Trials Logo

Clinical Trial Summary

Evaluate PFS of PD-1 Toripalimab Combined With Anlotinib in Subjects With unresectable locally advanced or metastatic acral malignant melanoma


Clinical Trial Description

Malignant melanoma (MM) is one of the most malignant tumors. It is easy to metastasize at an early stage, has a high mortality rate, and its incidence is increasing year by year. This study aims to evaluate the effectiveness and safety of the combined application of Anlotinib Hydrochloride Capsules and Toripalimab in the treatment of unresectable stage III and stage IV acral malignant melanoma confirmed by pathology. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05087602
Study type Interventional
Source Qilu Hospital of Shandong University
Contact cuihua yi
Phone 18560082871
Email 552029978@qq.comqq.com
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2021
Completion date October 30, 2023